Reduced CD34+ Stem Cells Predicts CV Outcome in T2DM
Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ cells
THURSDAY, Nov. 10, 2016 (HealthDay News) -- Reduced baseline levels of circulating CD34+ stem cells predict adverse cardiovascular outcomes for patients with type 2 diabetes, according to a study published online Nov. 4 in Diabetes Care.
Gian Paolo Fadini, M.D., Ph.D., from the University of Padova in Italy, and colleagues monitored a cohort of 187 patients with type 2 diabetes for a median of 6.1 years. Six stem/progenitor cell phenotypes were measured in peripheral blood at baseline, based on expression of CD34, CD133, and KDR.
The researchers found that the primary outcome of time to a first cardiovascular event plus hospitalization for cardiovascular causes occurred in 48 patients (4.5/100 patient-years). Significantly lower CD34+ and CD34+CD133+ cells were seen in patients with versus those without incident cardiovascular events. The rates of cardiovascular events were higher in patients with below median levels of CD34+ and CD34+CD133+. Reduced CD34+ and CD34+CD133+ cell count independently predicted future events in hazard regression analyses (hazard ratios, 2.21 and 2.98, respectively). C statistics, continuous net reclassification improvement, and/or integrated discrimination index were improved with addition of the CD34+ cell count to the reference model or the U.K. Prospective Diabetes Study risk engine.
"In patients with type 2 diabetes, a reduced baseline level of circulating CD34+ stem cells predicts adverse cardiovascular outcomes up to six years later and improves risk stratification," the authors write.